Category: Drug Discovery
Drug Discovery market research reports by DelveInsight
-
Chronic Spontaneous Urticaria - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s analysis, the Chronic Spontaneous Urticaria Market Size in the 7MM was valued at approximately USD 2,173.3 million in 2023. Over the forecast period from 2024 to 2034, this market is projected to grow at a CAGR of more than 10%, driven by the introduction o ... Read More
-
Acromegaly- Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights According to the estimates, the Acromegaly market size in the 7MM is ~USD 1,300 million in 2023. In 2023, among all the therapies, the highest Acromegaly market revenue was generated by somatostatin, i.e., ~USD 300 million, followed by growth hormone antagonist, i.e., ~USD 90 million ... Read More
-
Ewing Sarcoma - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the US accounted for the maximum share of the Ewing sarcoma Treatment Market in the 7MM, i.e., nearly 53%. A molecular-targeted therapy with minimal risk of late toxicities would be beneficial because most Ewing sarcoma Patients are under 20 years old. Although there is no st ... Read More
-
Epidermolysis Bullosa - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the market size of epidermolysis bullosa was highest in the US among the 7MM, accounting for approximately USD 1,300 million, which is further expected to increase by 2034. Epidermolysis bullosa simplex (EBS) is the least severe type of epidermolysis bullosa, and many individ ... Read More
-
Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the 7MM reported approximately 15,840 thousand diagnosed prevalent cases of Alzheimer’s disease, reflecting a significant disease burden. This high prevalence underscores the need for innovative treatments to address the rising impact on healthcare systems and patient care. I ... Read More
-
Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights The heparin-induced thrombocytopenia market size in the 7MM is estimated to be around ~USD 128 million, in 2023. Heparin-induced thrombocytopenia is characterized by a rapid decrease in platelet count occurring 5–14 days after the initiation of heparin therapy. It is primarily caused ... Read More
-
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
Key Highlights Among the 7MM, the United States captured the highest KRAS inhibitors market size in 2023, accounting for nearly 70% of the total KRAS Inhibitor market share. Among the approved KRAS Inhibitor therapies in the United States, KRAZATI is expected to have the edge over LUMAKRAS in revenu ... Read More
-
Oligometastatic Disease - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s patient-based forecasting model, the oligometastatic disease market size in the 7MM was around USD 1,900 million in 2023, which is expected to significantly increase over the forecast period (2024-2034), owing to an increase in the cases and the launch of n ... Read More
-
Postpartum Depression - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights The Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 million in 2023. Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Market Size of ~USD 25 Million in 2023. Among the seven major countries, the Postpartum Depression diagn ... Read More
-
B-cell Lymphoma- Pipeline Insight, 2025
DelveInsight’s, “B-cell Lymphoma- Pipeline Insight, 2025” report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutic ... Read More
-
Diabetic Nephropathy- Pipeline Insight, 2025
DelveInsight’s, “Diabetic Nephropathy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the the ... Read More
-
Sarcopenia - Pipeline Insight, 2025
DelveInsight’s, “Sarcopenia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Sarcopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessmen ... Read More
-
Chronic Spinal Cord Injury- Pipeline Insight, 2025
DelveInsight’s, “Chronic Spinal Cord Injury- Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Chronic Spinal Cord Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also cove ... Read More
-
Huntington’s Disease - Pipeline Insight, 2025
DelveInsight’s, “Huntington’s Disease - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the t ... Read More
-
Metastatic Colorectal Cancer - Pipeline Insight, 2025
DelveInsight’s, “Metastatic Colorectal Cancer - Pipeline Insight, 2025” report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
-
Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025
DelveInsight’s, “Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als ... Read More
-
Microbiome Disease- Pipeline Insight, 2025
DelveInsight’s, “Microbiome Disease- Pipeline Insight, 2025” report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in Microbiome Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the thera ... Read More
-
Hypertriglyceridemia - Pipeline Insight, 2025
DelveInsight’s, “Hypertriglyceridemia - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the th ... Read More
-
5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) - Pipeline Insight, 2025
“5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-Lipoxygenase Inhibitor (Arachidonate 5-Lipoxygenase Inhibitor) deve ... Read More
-
Angiotensin Receptor Agonist - Pipeline Insight, 2025
“Angiotensin Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiotensin Receptor Agonist development. The report provides detailed coverage of the pipeline landscape ... Read More
-
Interleukin-23 (IL-23) Inhibitor - Pipeline Insight, 2025
“Interleukin-23 (IL-23) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-23 (IL-23) Inhibitor development. The report provides detailed coverage of the pipeline l ... Read More
-
Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2025
“Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Kv1.3 Potassium Channel Blockers development. The report provides detailed coverage of the pipeline l ... Read More
-
Sigma Receptor Agonist - Pipeline Insight, 2025
“Sigma Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sigma Receptor Agonist development. The report provides detailed coverage of the pipeline landscape for this me ... Read More
-
Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2025
DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline landscape. It covers the pipeline drug profiles, includ ... Read More
-
TYK2 kinase inhibitors - Pipeline Insight, 2025
DelveInsight’s, “TYK2 Kinase Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 Kinase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
Research Assistance
